Literature DB >> 10958691

CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.

M E Garber1, T P Mayall, E M Suess, J Meisenhelder, N E Thompson, K A Jones.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) Tat interacts with cyclin T1 (CycT1), a regulatory partner of CDK9 in the positive transcription elongation factor (P-TEFb) complex, and binds cooperatively with CycT1 to TAR RNA to recruit P-TEFb and promote transcription elongation. We show here that Tat also stimulates phosphorylation of affinity-purified core RNA polymerase II and glutathione S-transferase-C-terminal-domain substrates by CycT1-CDK9, but not CycH-CDK7, in vitro. Interestingly, incubation of recombinant Tat-P-TEFb complexes with ATP enhanced binding to TAR RNA dramatically, and the C-terminal half of CycT1 masked binding of Tat to TAR RNA in the absence of ATP. ATP incubation lead to autophosphorylation of CDK9 at multiple C-terminal Ser and Thr residues, and full-length CycT1 (amino acids 728) [CycT1(1-728)], but not truncated CycT1(1-303), was also phosphorylated by CDK9. P-TEFb complexes containing a catalytically inactive CDK9 mutant (D167N) bound TAR RNA weakly and independently of ATP, as did a C-terminal truncated CDK9 mutant that was catalytically active but unable to undergo autophosphorylation. Analysis of different Tat proteins revealed that the 101-amino-acid SF2 HIV-1 Tat was unable to bind TAR with CycT1(1-303) in the absence of phosphorylated CDK9, whereas unphosphorylated CDK9 strongly blocked binding of HIV-2 Tat to TAR RNA in a manner that was reversed upon autophosphorylation. Replacement of CDK9 phosphorylation sites with negatively charged residues restored binding of CycT1(1-303)-D167N-Tat, and rendered D167N a more potent inhibitor of transcription in vitro. Taken together, these results demonstrate that CDK9 phosphorylation is required for high-affinity binding of Tat-P-TEFb to TAR RNA and that the state of P-TEFb phosphorylation may regulate Tat transactivation in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958691      PMCID: PMC88771          DOI: 10.1128/MCB.20.18.6958-6969.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  59 in total

Review 1.  Interplay between positive and negative elongation factors: drawing a new view of DRB.

Authors:  Y Yamaguchi; T Wada; H Handa
Journal:  Genes Cells       Date:  1998-01       Impact factor: 1.891

2.  Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages.

Authors:  Q Zhou; D Chen; E Pierstorff; K Luo
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

3.  PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.

Authors:  M O Gold; X Yang; C H Herrmann; A P Rice
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

5.  Identification of multiple cyclin subunits of human P-TEFb.

Authors:  J Peng; Y Zhu; J T Milton; D H Price
Journal:  Genes Dev       Date:  1998-03-01       Impact factor: 11.361

6.  Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation.

Authors:  F Wu-Baer; W S Lane; R B Gaynor
Journal:  J Mol Biol       Date:  1998-03-27       Impact factor: 5.469

7.  The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.

Authors:  T P Cujec; H Okamoto; K Fujinaga; J Meyer; H Chamberlin; D O Morgan; B M Peterlin
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

Review 8.  HIV-1 Tat: coping with negative elongation factors.

Authors:  M E Garber; K A Jones
Journal:  Curr Opin Immunol       Date:  1999-08       Impact factor: 7.486

9.  DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs.

Authors:  T Wada; T Takagi; Y Yamaguchi; A Ferdous; T Imai; S Hirose; S Sugimoto; K Yano; G A Hartzog; F Winston; S Buratowski; H Handa
Journal:  Genes Dev       Date:  1998-02-01       Impact factor: 11.361

10.  Evidence that Spt4, Spt5, and Spt6 control transcription elongation by RNA polymerase II in Saccharomyces cerevisiae.

Authors:  G A Hartzog; T Wada; H Handa; F Winston
Journal:  Genes Dev       Date:  1998-02-01       Impact factor: 11.361

View more
  76 in total

1.  Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.

Authors:  Cyril F Bourgeois; Young Kyeung Kim; Mark J Churcher; Michelle J West; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes.

Authors:  Ran Taube; Xin Lin; Dan Irwin; Koh Fujinaga; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

3.  TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication.

Authors:  Sara Richter; Yueh-Hsin Ping; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

Review 4.  RNA polymerase II elongation control.

Authors:  Qiang Zhou; Tiandao Li; David H Price
Journal:  Annu Rev Biochem       Date:  2012-03-09       Impact factor: 23.643

5.  Cross-interaction between JC virus agnoprotein and human immunodeficiency virus type 1 (HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial cells.

Authors:  Dorota Kaniowska; Rafal Kaminski; Shohreh Amini; Sujatha Radhakrishnan; Jay Rappaport; Edward Johnson; Kamel Khalili; Luis Del Valle; Armine Darbinyan
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.

Authors:  Nathan P Gomes; Glen Bjerke; Briardo Llorente; Stephanie A Szostek; Beverly M Emerson; Joaquin M Espinosa
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

7.  Tip110 protein binds to unphosphorylated RNA polymerase II and promotes its phosphorylation and HIV-1 long terminal repeat transcription.

Authors:  Weina Zhao; Ying Liu; Khalid Amine Timani; Johnny J He
Journal:  J Biol Chem       Date:  2013-11-11       Impact factor: 5.157

8.  Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation.

Authors:  Matjaz Barboric; Fan Zhang; Mojca Besenicar; Ana Plemenitas; B Matija Peterlin
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation.

Authors:  Sonja Baumli; Graziano Lolli; Edward D Lowe; Sonia Troiani; Luisa Rusconi; Alex N Bullock; Judit E Debreczeni; Stefan Knapp; Louise N Johnson
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

10.  Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1.

Authors:  Jorge Espinoza-Derout; Michael Wagner; Louis Salciccioli; Jason M Lazar; Sikha Bhaduri; Eduardo Mascareno; Brahim Chaqour; M A Q Siddiqui
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.